This morning we watched Illumina drop -1.9% to a price of $139.77 per share. The large-cap Medical Specialities company is now trading -34.63% below its average target price of $213.82. Analysts have set target prices ranging from $125.0 to $318.0 per share for Illumina, and have given the stock an average rating of hold.
Illumina's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 4.0%. The stock's short ratio is 4.38. The company's insiders own 0.27% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 93.5%. In conclusion, we believe there is mixed market sentiment regarding Illumina.
Institutions Invested in Illumina
|2023-06-30||Vanguard Group Inc||10%||15,630,823||$2,184,720,197|
|2023-06-30||Baillie Gifford and Company||9%||13,973,317||$1,953,050,576|
|2023-06-30||State Street Corporation||4%||6,715,664||$938,648,385|
|2023-06-30||Edgewood Management Llc||4%||5,572,973||$778,934,460|
|2023-06-30||Wellington Management Group, LLP||3%||5,275,549||$737,363,506|
|2023-06-30||Polen Capital Management, LLC||3%||5,097,461||$712,472,145|
|2023-06-30||Janus Henderson Group PLC||3%||4,783,774||$668,628,112|
|2023-06-30||Loomis Sayles & Company, LP||2%||3,799,690||$531,082,687|